VitaNova Life Sciences Gross Margin Growth & History (VNOV)
VitaNova Life Sciences's gross margin was 30.10% for fiscal 2026.
View full VitaNova Life Sciences company overviewVitaNova Life Sciences annual gross margin history
2023
2024
2025
2026
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2026 | 2026-04-30 | 30.10% | −29.09 pp |
| 2025 | 2025-04-30 | 59.19% | −6.99 pp |
| 2024 | 2024-04-30 | 66.18% | −33.82 pp |
| 2023 | 2023-04-30 | 100.00% | — |
VitaNova Life Sciences quarterly gross margin
Q2.18
Q3.18
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q4 2026 | 2026-04-30 | 14.83% | −44.43 pp |
| Q3 2026 | 2026-01-31 | 44.58% | −16.82 pp |
| Q2 2026 | 2025-10-31 | 61.06% | +7.72 pp |
| Q1 2026 | 2025-07-31 | 66.20% | −1.25 pp |
| Q4 2025 | 2025-04-30 | 59.26% | −5.31 pp |
| Q3 2025 | 2025-01-31 | 61.40% | −38.60 pp |
| Q2 2025 | 2024-10-31 | 53.35% | — |
| Q1 2025 | 2024-07-31 | 67.45% | — |
| Q4 2024 | 2024-04-30 | 64.56% | — |
| Q3 2024 | 2024-01-31 | 100.00% | — |
| Q3 2018 · Oct 31 | 2017-10-31 | 41.24% | — |
| Q2 2018 | 2017-07-31 | 84.24% | — |
VitaNova Life Sciences gross margin trends
Between the periods ended 2023-04-30 and 2026-04-30, VitaNova Life Sciences's gross margin decreased from 100.00% to 30.10%, a change of −69.90 percentage points. The latest reported quarter, Q4 2026, shows 14.83%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review VitaNova Life Sciences source filings ↗